Shares of Chimerix Inc. (NASDAQ:CMRX) were down 2.1% on Tuesday . The company traded as low as $4.49 and last traded at $4.56, with a volume of 130,484 shares. The stock had previously closed at $4.66.

A number of analysts have weighed in on CMRX shares. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Wednesday, August 10th. FBR & Co reissued a “hold” rating on shares of Chimerix in a report on Sunday, July 17th. Finally, JPMorgan Chase & Co. reissued a “hold” rating and set a $7.00 price objective on shares of Chimerix in a report on Tuesday, August 9th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Chimerix currently has a consensus rating of “Hold” and an average price target of $16.18.

The stock’s 50-day moving average is $4.11 and its 200 day moving average is $4.99. The stock’s market cap is $202.88 million.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.12. The company earned $1.80 million during the quarter, compared to analysts’ expectations of $1.98 million. Equities analysts anticipate that Chimerix Inc. will post ($1.78) earnings per share for the current fiscal year.

In other Chimerix news, Director Ernest Mario bought 50,000 shares of Chimerix stock in a transaction dated Friday, June 24th. The stock was bought at an average cost of $3.70 per share, for a total transaction of $185,000.00. Following the purchase, the director now owns 381,440 shares in the company, valued at approximately $1,411,328. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO M Michelle Berrey bought 13,188 shares of Chimerix stock in a transaction dated Friday, June 24th. The shares were acquired at an average price of $3.69 per share, with a total value of $48,663.72. Following the completion of the purchase, the chief executive officer now owns 258,821 shares in the company, valued at approximately $955,049.49. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Chimerix stock. Jennison Associates LLC raised its stake in shares of Chimerix Inc. (NASDAQ:CMRX) by 67.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,273,779 shares of the biopharmaceutical company’s stock after buying an additional 515,029 shares during the period. Jennison Associates LLC owned approximately 2.76% of Chimerix worth $11,400,000 as of its most recent filing with the SEC.

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.